# EDGAR Filing Document

**Accession Number:** 0001787518
**File Stem:** 0001213900-25-120398
**Filing Date:** 2025-12
**Character Count:** 38814
**Document Hash:** 5404fec9f0cbc3d222cc6752a0618a82
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-120398.hdr.sgml**: 20251211

**ACCESSION NUMBER**: 0001213900-25-120398

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251211

**DATE AS OF CHANGE**: 20251211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nukkleus Inc.
- **CENTRAL INDEX KEY:** 0001787518
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 383912845
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39341
- **FILM NUMBER:** 251563696

**BUSINESS ADDRESS:**
- **STREET 1:** 575 FIFTH AVENUE, 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-791-4663

**MAIL ADDRESS:**
- **STREET 1:** 575 FIFTH AVENUE, 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brilliant Acquisition Corp
- **DATE OF NAME CHANGE:** 20190909

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934

(Amendment No.)

---

| | |
|:---|:---|
| Filed by Registrant | ☒ |
| Filed by Party other than Registrant | ☐ |
| Check the appropriate box: |  |

---

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Materials Pursuant to §240.14a-12

---

| |
|:---|
| &nbsp;&nbsp;**Nukkleus Inc.** |
| &nbsp;&nbsp;(Name of Registrant as Specified In Its Charter) |

---

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

---

| | |
|:---|:---|
| Payment of Filing Fee (Check the appropriate box): | Payment of Filing Fee (Check the appropriate box): |
| ☒ | No fee required |
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

---

**Nukkleus Inc.**

**575 Fifth Ave, 14th floor**

**New York, New York 10017**

**212-791-4663**

**PROXY STATEMENT SUPPLEMENT**

**Dated December 11, 2025**

*The following disclosures in this proxy supplement (the "Supplement") supplement, and should be read in conjunction with, the disclosures contained in the definitive proxy statement (the "Definitive Proxy Statement") of Nukkleus Inc. (the "Company"), filed with the Securities and Exchange Commission (the "SEC") on November 24, 2025, which in turn should be read in its entirety. The Unaudited Pro Forma Condensed Combined Financial Statements contained in the Supplement amend and restate those provided for in the Definitive Proxy Statement. To the extent the information set forth herein differs from or updates information contained in the Definitive Proxy Statement, the information set forth herein shall supersede or supplement the information in the Definitive Proxy Statement. All other information in the Definitive Proxy Statement remains unchanged. Unless otherwise specified, page and section references listed below are references to pages and sections, respectively, in the Definitive Proxy Statement, not this Supplement.*

 

*As provided in the Definitive Proxy Statement, the Company is seeking stockholder approval of, among other things, (i) the Star Purchase Proposal, (ii) the Warrant Shares Proposal, (iii) the ELOC Issuance Proposal and (iv) the Preferred Stock Conversion Issuance Proposal.*

 

*Terms used herein, unless otherwise defined, have the meanings set forth in the Definitive Proxy Statement.*

**UPDATES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS**

The section titled "Unaudited Pro Forma Condensed Combined Financial Statements" beginning on page 37 of the Definitive Proxy Statement has been amended to reflect as pro forma adjustments transactions that resulted in the issuance by the Company of 5,549,502 shares of the Company's common stock, par value $0.0001 per share, subsequent to September 30, 2025.

**NUKKLEUS INC. AND SUBSIDIARIES**

**UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS**

***Star Acquisition***

On December 15, 2024, the Company entered into the Securities Purchase Agreement and Call Option, which was subsequently amended on each of February 11, 2025, May 13, 2025, June 15, 2025 and July 25, 2025. Said agreement, as amended, provided that the Company would acquire 51% of Star and the Star Equity Holders would grant the Company an option to purchase the balance of the equity. Mr. Shalom, who is the Chief Executive Officer and a director of the Company, is a controlling shareholder, Chief Executive Officer and a director of Star.

On September 15, 2025, the parties executed and delivered the Amended and Restated Securities Purchase Agreement with Star, the Star Equity Holders and Menachem Shalom, the representative of such shareholders, to memorialize the proposed Transaction. Pursuant to the Star Agreement, the Company at closing will acquire 100% of the issued and outstanding capital of Star in consideration of (i) $21,000,000, to be paid by a 12-month $16,000,000 promissory note and the balance in $5,000,000 cash, less any amounts lent to Star from the Company since the Original Star Purchase Agreement, (ii) 4,770,340 shares of common stock of the Company (the "Shares"), (iii) a five-year warrant (the "Star Warrant") to purchase an aggregate of 12,017,648 shares of the Company's common stock for an exercise price of $1.50 per share, (iv) $3,000,000 in cash and (v) a 6-month promissory note in the principal amount of $3,000,000, which shall accrue interest at the rate of 8%.The Shares, Star Warrants, cash and the 6-month note will be assigned by Star to the Star Equity Holders pro ratably. If the Star Agreement is terminated as a result of the Company failing to perform or observe the covenants or agreements of the Company or if Company fails to maintain its listing on Nasdaq, Star shall be entitled to a payment from the Company in the amount of $3,000,000.

The closing of the Transaction is subject to customary closing conditions, including approval by the Company's shareholders as required under applicable Nasdaq listing rules. As a result of the above transaction, the Shares issued to Star and assigned to the Star Equity Holders represents 28.7% of the issued and outstanding shares of Common Stock as of the Record Date. Further, assuming the Star Equity Holders have exercised the Star Warrant, the Star Equity Holders would hold an aggregate of 16,787,988 shares of Common Stock representing 100.9% of the issued and outstanding shares of Common Stock of the Company as of the Record Date.

The unaudited pro forma condensed combined financial information is presented to illustrate the effects of the acquisition of Star, as if it had occurred on January 1, 2024, the beginning of the most recently completed fiscal year preceding the Star Acquisition. The unaudited pro forma condensed combined financial statements were prepared in accordance with Article 11 of Regulation S-X, as amended by Securities and Exchange Commission (the "SEC") Final Rule Release No. 33-10786, *Amendments to Financial Disclosures About Acquired and Disposed Businesses* and are presented to illustrate the estimated effects of the Star Acquisition and Related Transactions.

The unaudited pro forma condensed combined balance sheet as of September 30, 2025 and the unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2025 and for the year ended December 31, 2024 are based upon, derived from and should be read in conjunction with Nukk's historical unaudited condensed consolidated financial statements for the nine months ended September 30, 2025 and Nukk's historical audited consolidated financial statements for the three months ended December 31, 2024 and for the year ended September 30, 2024 (which are available in the Company's Annual Report on Form 10-K for the three months ended December 31, 2024 and the year ended September 30, 2024, as filed with the SEC on May 8, 2025 and February 10, 2025, respectively), as amended on each of July 9, 2025 and April 14, 2025 and the unaudited historical financial statements as of September 30, 2025 and for the nine months ended September 30, 2025 of Star and the audited historical financial statements of Star as of and for the year ended December 31, 2024 included in this proxy statement.

The historical combined financial information has been adjusted to give pro forma effect to reflect the accounting for the Star Acquisition in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). In the opinion of management, all adjustments necessary to present fairly the unaudited pro forma condensed combined financial information have been made. The assumptions underlying the pro forma adjustments are described fully in the accompanying notes, which should be read in conjunction with the unaudited pro forma condensed combined financial information.

The Star Acquisition is being accounted for as a business combination using the acquisition method of accounting under the provisions of Accounting Standards Codification ("ASC") Topic 805, "Business Combinations" ("ASC 805"). Under ASC 805, all assets acquired and liabilities assumed are recorded at their acquisition date fair value. The allocation of the purchase price as reflected in the unaudited pro forma condensed combined financial information is based upon management's internally developed preliminary estimates of the fair market value of the assets acquired and liabilities assumed, as if the Star Acquisition had occurred on the aforementioned dates. This allocation of the purchase price depends upon certain estimates and assumptions, all of which are preliminary and, in some instances, are incomplete and have been made solely for the purpose of developing the unaudited pro forma condensed combined financial information. Any adjustments to the preliminary estimated fair value amounts could have a significant impact on the unaudited pro forma condensed combined financial information contained herein, and our future results of operations and financial position.

The unaudited pro forma condensed combined financial information is not necessarily indicative of the combined financial position or results of operations that would have been realized had the Star Acquisition occurred as of the dates indicated, nor is it meant to be indicative of any anticipated combined financial position or future results of operations that the Company will experience after the Star Acquisition.

**NUKKLEUS INC. AND SUBSIDIARIES**

**UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET**

**AS OF SEPTEMBER 30, 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nukkleus<br> Inc.** | **Acquisition of<br> Star26** | **Transaction<br> Adjustments<br> (Note 4)** | **Pro Forma<br> Combined** |
| **Assets** | | | | |
| Current assets |  |  |  |  |
| Cash and cash equivalents | $7611465 | 924000 | $(3500000) **A** | $5035465 |
| Restricted Cash |  | 60000 |  | 60000 |
| Short term bank deposits |  | 119000 |  | 119000 |
| Marketable securities |  | 289000 |  | 289000 |
| Digital assets | 32182 |  | (11196) **F** | 20986 |
| Accounts Receivable |  | 478000 |  | 478000 |
| Note recievable - related party | 4500000 |  | (4500000) **A** |  |
| Due from Affiliates | 243915 |  |  | 243915 |
| Currrent assets from discountinued operations |  |  |  |  |
| Inventory |  | 1544000 |  | 1544000 |
| Other current assets | 730894 | 412000 | (125) **F** | 1142769 |
| Total current assets | 13118456 | 3826000 | (8000000) | 8933135 |
| Funds in respect of employee rights upon retirement |  | 79000 |  | 79000 |
| Long-term loan to other Company |  | 2432000 |  | 2432000 |
| Deferred taxes |  | 284000 |  | 284000 |
| Intangible assets, net |  | 134000 | 200435 **B** | 334435 |
| Goodwill |  |  | 76600948 **B** | 76600948 |
| Operating lease right-of-use assets | 153569 | 1046000 |  | 1199569 |
| Other assets from discontineud operations |  |  |  |  |
| Property and equipment, net | 15883 | 172000 | - | 187883 |
| **Total assets** | $13287908 | 7973000 | $68790062 | $90050970 |
| **Liabilities and stockholders' equity (deficit)** |  |  |  |  |
| Current liabilities |  |  |  |  |
| Short term loans | $- | 1903000 |  | $1903000 |
| Short term loans – related party |  | 4500000 |  | 4500000 |
| Intercompany |  |  |  |  |
| Accounts payable | 87420 | 865000 |  | 952420 |
| Convertible notes payable, net |  |  |  |  |
| Note Payable, net |  |  | 19000000 **C** | 19000000 |
| Due to affiliates | 233068 |  |  | 233068 |
| Loans payable – related parties, current | 1566988 |  |  | 1566988 |
| Interest payable – related parties, current | 108417 |  |  | 108417 |
| Accrued expenses and other current liabilities | 816224 | 1630000 | 42091 **B** | 2488315 |
| Accrued expenses and other current liabilities – related party |  | 548000 |  | 548000 |
| Derivative liabilities |  |  |  |  |
| Stock purchase warrants, liability classified | 40740193 | 203000 | (3048532) **F** | 37894661 |
| Current liabilities from discontinued operations |  |  |  |  |
| Operating lease liabilities, current portion | 78575 | 316000 | - | 394575 |
| Total current liabilities | 43630885 | 9965000 | 15993559 | 69589444 |
| Liability for employees' rights upon retirement |  | 112000 |  | 112000 |
| Loans payable - related parties, net of current portion |  |  |  |  |
| Interest payable - related parties, net of current portion |  |  |  |  |
| Non-current liabilities from discontinued operations |  |  |  |  |
| Long-term loans from Banks |  | 537000 |  | 537000 |
| Operating lease liabilities | 74994 | 752000 | - | 826994 |
| **Total liabilities** | 43705879 | 11366000 | 15993559 | 71065438 |
| Commitments and contingencies |  |  |  |  |
| **Stockholders' equity** |  |  |  |  |
| Preferred stock ($0.0001 par value; 15,000,000 shares authorized; 200 shares issued and outstanding at September 30, 2025) |  |  |  |  |
| Common stock ($0.0001 par value; 150,000,000 shares authorized; 11,096,264 shares issued and outstanding at September 30, 2025; on a proforma basis 21,416,106 shares issued and outstanding) | 1110 |  | 477 **D** | 2142 |
|  |  |  | 555 **F** |  |
| Class A common stock, par value $0.0001 per share, 250,000,000 shares authorized and 5,075,000 shares issued and outstanding as of September 30, 2025 |  | 508 | (508) **E** |  |
| Class B common stock, par value $0.0001 per share, 50,000,000 shares authorized and 6,250,000 shares issued and outstanding as of September 30, 2025 |  | 625 | (625) **E** |  |
| Additional paid in capital | 81047703 | 322868 | 46038947 **D** | 149113270 |
|  |  |  | 21703752 **F** |  |
| Other comprehensive income | (2277) | (74000) | 74000 **E** | (2277) |
| Accumulated deficit | (111464507) | (3647000) | 3647000 **E** | (130131603) |
|  |  |  | (18667096) **F** |  |
| **Total Nukkleus Inc. stockholders' equity (deficit)** | (30417971) | (3397000) | 52796503 | 18981532 |
| Non-controlling interest | - | 4000 | - | 4000 |
| **Total stockholders' equity (deficit)** | (30417971) | (3393000) | 52796503 | 18985532 |
| **Total liabilities and stockholders' equity (deficit)** | $13287908 | 7973000 | $68790062 | $90050970 |

---

Refer to accompanying notes

**NUKKLEUS INC. AND SUBSIDIARIES**

**UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS**

**FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Nukkleus<br> Inc.** | **Acquisition of<br> Star26** | **Disposition of<br> DRFQ** | **Adjustments<br> (Note 5)** | **Pro Forma<br> Combined** |
| REVENUES |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Revenue - other | $- | 2711000 | - | $— | 2711000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues |  | 2711000 |  |  | 2711000 |
| COSTS OF REVENUES |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of revenue - other | - | 2355000 | - | - | 2355000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total costs of revenues |  | 2355000 |  |  | 2355000 |
| GROSS PROFIT (LOSS) |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Gross Profit (loss) - other | - | 356000 | - | - | 356000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Gross Profit (Loss) |  | 356000 |  |  | 356000 |
| OPERATING EXPENSES |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Professional fees | 6051719 |  |  | 11588400 **BB** | 17640119 |
| &nbsp;&nbsp;&nbsp;Compensation and related benefits | 365988 |  |  | 4567500 **BB** | 4933488 |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets |  | 63000 |  | 2500 **AA** | 65500 |
| &nbsp;&nbsp;&nbsp;Disposal of intangible assets |  | 1812000 |  |  | 1812000 |
| &nbsp;&nbsp;&nbsp;Other general and administrative | 909275 | 1867000 |  |  | 2776275 |
| &nbsp;&nbsp;&nbsp;Other general and administrative - related party | - | 258000 |  |  | 258000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 7326982 | 4000000 |  | 16158400 | 27485382 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**LOSS FROM OPERATIONS** | **(7326982)** | **(3644000)** |  | **(16158400)** | **(27129382)** |
|  |  |  |  |  | **-** |
| OTHER (EXPENSE) INCOME: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (407971) | 423000 |  |  | 15029 |
| &nbsp;&nbsp;&nbsp;Interest expense - related parties | (64306) |  |  |  | (64306) |
| &nbsp;&nbsp;&nbsp;Penalty - late registration | (800000) |  |  |  | (800000) |
| &nbsp;&nbsp;&nbsp;Loss on debt extinguishment | (7484152) |  |  |  | (7484152) |
| &nbsp;&nbsp;&nbsp;Change in fair value of liability classified stock purchase warrants | 123369695 |  |  |  | 123369695 |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | 587790 |  |  |  | 587790 |
| &nbsp;&nbsp;&nbsp;Change in fair value of digital assets | (967818) |  |  | (2511196) **CC** | (3479014) |
| &nbsp;&nbsp;&nbsp;Gain on disposition of subsdiary | 2491485 |  |  |  | 2491485 |
| &nbsp;&nbsp;&nbsp;Day one loss on private placement | (19605956) |  |  |  | (19605956) |
| &nbsp;&nbsp;&nbsp;Other income (expense) | 280422 | - |  |  | 280422 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total other income (expense), net** | 97399189 | 423000 |  | (2511196) | 95310993 |
| INCOME (LOSS) BEFORE INCOME TAXES | 90072207 | (3221000) |  | (18669596) | 68181611 |
| &nbsp;&nbsp;&nbsp;Income tax expense | - | 49000 |  | - | 49000 |
| NET INCOME (LOSS) FROM CONTINUING OPERATIONS | 90072207 | (3172000) |  | (18669596) | 68230611 |
| Net Income (loss) from discontinued operations | (460971) | - | 460971 |  | - |
| Net Income (Loss) | 89611236 | (3172000) | 460971 | (18669596) | 68230611 |
| Net income (loss) attributable to noncontrolling interest | - | (82000) |  |  | (82000) |
| Net income (loss) attributable to Nukkleus, Inc. | 89611236 | (3090000) | 460971 | (18669596) | 68312611 |
| Income (loss) per common share, basic: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) from continuing operations, net of tax | 14.74 |  |  | (1.81) | 4.15 |
| &nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations, net of tax | (0.08) |  |  | - | - |
| &nbsp;&nbsp;&nbsp;Net income (loss) | 14.66 |  |  | (1.81) | 4.15 |
| Income (loss) per common share, diluted: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) from continuing operations, net of tax | 11.53 |  |  | (1.81) | 3.76 |
| &nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations, net of tax | (0.06) |  |  | - | - |
| &nbsp;&nbsp;&nbsp;Net income (loss) | 11.47 |  |  | (1.81) | 3.76 |
| Weighted-average shares outstanding: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 6111279 |  |  | 10319842 | 16431121 |
| &nbsp;&nbsp;&nbsp;Diluted | 7813592 |  |  | 10319842 | 18133434 |

---

Refer to accompanying notes

**NUKKLEUS INC. AND SUBSIDIARIES**

**UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS**

**FOR THE YEAR ENDED DECEMBER 31, 2024**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Nukkleus<br> Inc.** | **Acquisition of<br> Star26** | **Disposition of<br> DRFQ** | **Transaction<br> Adjustments<br> (Note 4)** | **Pro Forma<br> Combined** |
| REVENUES |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Revenue - other | $- | 4994000 | - |  | $4994000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues |  | 4994000 |  |  | 4994000 |
| COSTS OF REVENUES |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of revenue - other | - | 3808000 | - | - | 3808000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total costs of revenues |  | 3808000 |  |  | 3808000 |
| GROSS PROFIT (LOSS) |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Gross Profit (loss) - other | - | 1186000 | - | - | 1186000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Gross Profit (Loss) |  | 1186000 |  |  | 1186000 |
| OPERATING EXPENSES |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Professional fees | 7596190 |  |  |  | 7596190 |
| &nbsp;&nbsp;&nbsp;Compensation and related benefits | 1270799 |  |  |  | 1270799 |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets |  | 74000 |  | 13333 **AA** | 87333 |
| &nbsp;&nbsp;&nbsp;Other general and administrative | 692221 | 1296000 |  |  | 1988221 |
| &nbsp;&nbsp;&nbsp;Other general and administrative |  | 307000 |  |  | 307000 |
| &nbsp;&nbsp;&nbsp;Impairment loss | 293413 |  |  |  | 293413 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 9852622 | 1677000 |  | 13333 | 11542955 |
| &nbsp;&nbsp;&nbsp;**LOSS FROM OPERATIONS** | **(9852622)** | **(491000)** |  | **(13333)** | **(10356955)** |
| OTHER (EXPENSE) INCOME: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (696826) | (105000) |  |  | (801826) |
| &nbsp;&nbsp;&nbsp;Interest expense - related parties | (33083) | (38000) |  |  | (71083) |
| &nbsp;&nbsp;&nbsp;Loss on settlement of vendor obligations | (494619) |  |  |  | (494619) |
| &nbsp;&nbsp;&nbsp;Gain on extinguishment of vendor obligations | 158400 |  |  |  | 158400 |
| &nbsp;&nbsp;&nbsp;Gain on extinguishment of due to affiliates | 144052 |  |  |  | 144052 |
| &nbsp;&nbsp;&nbsp;Gain on sale of investment | 63759 |  |  |  | 63759 |
| &nbsp;&nbsp;&nbsp;Day one loss on stock purchase warrants issued in connection with private placement | (13533404) |  |  |  | (13533404) |
| &nbsp;&nbsp;&nbsp;Day one loss of stock purchase warrants issued in connection with conversion of convertible notes | (663408) |  |  |  | (663408) |
| &nbsp;&nbsp;&nbsp;Change in fair value of liability classified stock purchase warrants | (140584780) |  |  |  | (140584780) |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | (624888) |  |  |  | (624888) |
| &nbsp;&nbsp;&nbsp;Loss on reclassification of stock purchase warrants from equity-classified to liability-classified | (45784) |  |  |  | (45784) |
| &nbsp;&nbsp;&nbsp;Gain on disposition of subsidiary |  |  |  | 2074600 **BB** | 2074600 |
| &nbsp;&nbsp;&nbsp;Other income (expense) | - | 55000 |  |  | 55000 |
| &nbsp;&nbsp;&nbsp;**Total other income (expense), net** | (156310582) | (88000) |  | 2074600 | (154323982) |
| LOSS BEFORE INCOME TAXES | (166163203) | (579000) |  | 2061267 | (164680937) |
| &nbsp;&nbsp;&nbsp;Income tax expense | - | 24000 |  | - | 24000 |
| NET LOSS FROM CONTINUING OPERATIONS | $(166163203) | (555000) |  | 2061267 | (164656937) |
| Net loss from discontinued operations | (1013666) | - | 1013666 |  | - |
| NET LOSS | (167176869) | (555000) | 1013666 | 2061267 | $(164656937) |
| Net loss attributable to noncontrolling interest | **-** | (271950) | **-** | **-** | (271950) |
| Net loss attributable to Nukkleus, Inc. | (167176869) | (283050) | 1013666 | 2061267 | (164384987) |
| Income (loss) per common share, basic: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) from continuing operations, net of tax | $(33.70) |  |  | 0.43 | $(16.95) |
| &nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations, net of tax | $(0.21) |  |  | - | $- |
| &nbsp;&nbsp;&nbsp;Net income (loss) | $(33.91) |  |  | 0.43 | $(16.95) |
| Income (loss) per common share, diluted: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) from continuing operations, net of tax | $(33.70) |  |  | 0.43 | $(16.95) |
| &nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations, net of tax | $(0.21) |  |  | - | $- |
| &nbsp;&nbsp;&nbsp;Net income (loss) | $(33.91) |  |  | 0.43 | $(16.95) |
| Weighted-average shares outstanding: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 4930531 |  |  | 4770340 | 9700871 |
| &nbsp;&nbsp;&nbsp;Diluted | 4930531 |  |  | 4770340 | 9700871 |

---

Refer to accompanying notes

**NUKKLEUS INC. AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS**

**Note 1 - Description of Transaction**

On December 15, 2024, the Company entered into the Securities Purchase Agreement and Call Option, which was subsequently amended on each of February 11, 2025, May 13, 2025, June 15, 2025 and July 25, 2025. Said agreement, as amended, provided that the Company would acquire 51% of Star and the Star Equity Holders would grant the Company an option to purchase the balance of the equity. Mr. Shalom, who is the Chief Executive Officer and a director of the Company, is a controlling shareholder, Chief Executive Officer and a director of Star.

On September 15, 2025, the parties executed and delivered the Amended and Restated Securities Purchase Agreement with Star, the Star Equity Holders and Menachem Shalom, the representative of such shareholders, to memorialize the proposed Transaction. Pursuant to the Star Agreement, the Company at closing will acquire 100% of the issued and outstanding capital of Star in consideration of (i) $21,000,000, to be paid by a 12-month $16,000,000 promissory note and the balance in $5,000,000 cash, less any amounts lent to Star from the Company since the Original Star Purchase Agreement, (ii) 4,770,340 shares of common stock of the Company (the "Shares"), (iii) a five-year warrant (the "Star Warrant") to purchase an aggregate of 12,017,648 shares of the Company's common stock for an exercise price of $1.50 per share, (iv) $3,000,000 in cash and (v) a 6-month promissory note in the principal amount of $3,000,000, which shall accrue interest at the rate of 8%.The Shares, Star Warrants, cash and the 6-month note will be assigned by Star to the Star Equity Holders pro ratably. If the Star Agreement is terminated as a result of the Company failing to perform or observe the covenants or agreements of the Company or if Company fails to maintain its listing on Nasdaq, Star shall be entitled to a payment from the Company in the amount of $3,000,000.

As a result of the Settlement Agreement and subject to the closing of the acquisition of Star, the Company's business will be focused on the defense sector.

The allocation of the purchase price discussed below is preliminary. The final allocation of the purchase price will be determined at a later date and is dependent on a number of factors, including the final evaluation of the fair value of Star's tangible and identifiable intangible assets acquired and liabilities assumed. Such final adjustments, which may include other increases or decreases to amortization resulting from the allocation of the purchase price to amortizable tangible and intangible assets, along with the related income tax effect, may be material.

**NUKKLEUS INC. AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS**

The total consideration transferred is presented as follows:

---

| | |
|:---|:---|
| Purchase consideration: |  |
| &nbsp;&nbsp;&nbsp;4,770,340 shares of Nukk Common Stock, at fair value\* | $28335820 |
| &nbsp;&nbsp;&nbsp;12,017,648 warrants to purchase shares of Nukk Common Stock, at fair value | 18026472 |
| &nbsp;&nbsp;&nbsp;Notes payable | 19000000 |
| &nbsp;&nbsp;&nbsp;Cash paid | 8000000 |
| Total purchase consideration for 100% of Star | $73362292 |

---

\* based on closing stock price at December 10, 2025, most recent practicable date. Below is a table with a range of possible outcomes based on changes in the Company's stock price:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Current Value** | **Increase in <br> stock price <br> by 10%** | **Decrease in <br> stock price <br> by 10%** | **Increase in <br> stock price <br> by 50%** | **Decrease in <br> stock price <br> by 50%** |
| 4,770,340 shares of Nukk Common Stock, at fair value | 28335820 | 31169402 | 25502238 | 42503729 | 14167910 |
| Total purchase consideration | 73362292 | 76195874 | 70528710 | 87530201 | 59194382 |
| Goodwill | 76596948 | 79430530 | 73763366 | 90764858 | 62429038 |

---

The total preliminary estimated purchase consideration as shown in the table above is allocated to the tangible and intangible assets and liabilities of Star based on their estimated fair values, with any excess purchase consideration allocated to goodwill as follows.

---

| | |
|:---|:---|
| **Purchase Price Allocation** | **Adjusted<br> Balance** |
| Cash and Restricted Cash | $1103000 |
| Marketable Securities | 289000 |
| Accounts Receivable | 478000 |
| Inventory | 1544000 |
| Intangible assets | 334435 |
| Other assets | 3379000 |
| Goodwill | 76596948 |
| Operating lease right of use asset | 1046000 |
| Accounts payable and other current liabilities | (2607000) |
| Accounts payable and other current liabilities - related party | (548000) |
| Lease liability, current and non-current | (1068000) |
| Warrants – liability classified | (203000) |
| Deferred tax liability | (42091) |
| Loans | (4500000) |
| Loans - related party | (2440000) |
| &nbsp;&nbsp;&nbsp;Fair value of assets acquired | $73362292 |

---

**NUKKLEUS INC. AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS**

**Note 2 - Basis of Presentation**

The unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2025 was derived from the unaudited consolidated financial statements included in the Company's Quarterly Report on Form 10-Q ("the Q32025 Form 10-Q") for the three and nine months ended September 30, 2025, and the unaudited historical financial statements of Star for the nine months ended September 30, 2025, and has been prepared as if the Star Acquisition had occurred on January 1, 2024.

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2024 was derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-K ("the 2024 Form 10-K") for the three months ended December 31, 2024 and for the year ended September 30, 2024, and the audited historical financial statements of Star for the year ended December 31, 2024, and has been prepared as if the Star Acquisition had occurred on January 1, 2024.

The unaudited pro forma condensed combined balance sheet as of September 30, 2025 combines the consolidated balance sheet included in the Q32025 Form 10-Q with the historical audited balance sheet for Star as of September 30, 2025, and has been prepared as if the Star Acquisition had occurred on September 30, 2025. The unaudited pro forma combined financial information herein has been prepared to illustrate the effects of the Star Acquisition and Related Transaction in accordance with U.S. GAAP and pursuant to Article 11 of Regulation S-X.

The Star unaudited historical consolidated financial statements as of and for the nine months ended September 30, 2025 and the Star audited historical consolidated financial statements as of and for the year ended December 31, 2024 are included in this Proxy Statement. These unaudited pro forma condensed combined statements should be read in conjunction with such historical financial statements. The historical consolidated financial information has been adjusted to give pro forma effect to reflect the accounting for the Star Acquisition in accordance with U.S. GAAP.

The Company has accounted for the Star Acquisition under the acquisition method of accounting in accordance with the authoritative guidance on business combinations under the provisions of ASC 805. The allocation of the purchase price as reflected in the unaudited pro forma condensed combined financial information was based on a preliminary valuation of the assets acquired and liabilities assumed, and the accounting is subject to revision as more detailed analyses are completed and additional information about the fair value of assets acquired and liabilities assumed becomes available. The final purchase price allocation may include changes to the amount of intangible assets, goodwill, and deferred taxes, as well as other items. Accordingly, the pro forma adjustments are preliminary and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final purchase accounting may occur, and these differences could be material.

Assets acquired and liabilities assumed in a business combination that arise from contingencies must be recognized at fair value if the fair value can be reasonably estimated. If the fair value of an asset or liability that arises from a contingency cannot be determined, the asset or liability would be recognized in accordance with ASC 450, "Disclosure of Certain Loss Contingencies" ("ASC 450"). If the fair value is not determinable and the ASC 450 criteria are not met, no asset or liability would be recognized. Management is not aware of any material contingencies related to Star.

The unaudited pro forma condensed combined financial information is presented solely for informational purposes and is not necessarily indicative of the combined results of operations or financial position that might have been achieved for the periods presented, nor is it necessarily indicative of the future results of the combined company. The unaudited pro forma combined financial information does not reflect any cost savings from future operating synergies or integration activities, if any, or any revenue, tax, or other synergies, if any, that could result from the Star Acquisition.

**NUKKLEUS INC. AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS**

**Note 3 - Unaudited Pro Forma Condensed Combined Balance Sheet Adjustments**

&nbsp;&nbsp;&nbsp;&nbsp;**A.** Represents $3.5 million cash paid at closing and a $4.5 million advance paid prior to closing for the acquisition of Star

**B.** As a result of the acquisition of Star, in addition to the working capital accounts, the Company acquired intangibles of $0.2 million and goodwill. Goodwill is calculated as the difference between the fair value of the consideration transferred and the values assigned to the identifiable tangible and intangible assets acquired and liabilities assumed, including non-controlling interest. This adjustment of $76.6 million represents the adjustment to increase goodwill to its preliminary estimated fair value per the purchase price allocation.

**C.** Represents the issuance of a $19 million note balance as consideration for the Star acquisition.

**D.** Represents the issuance of 4,770,340 shares at $5.94 (the Company's used the closing price on Wednesday, December 10, 2025 as the most recent practicable date) and the issuance of 12,017,648 warrants at a fair value of $1.50 to the former shareholders of Star.

**E.** Represents the elimination of Star's historical equity

**F.** Represents the aggregate issuances of 2,079,502, 375,000, and 3,095,000 shares of the Company's common stock subsequent to September 30, 2025 in connection with cashless exercises of warrants, the Company's exercise of the second tranche of the Darwin warrant, and issuances pursuant to the 2025 Equity Plan, respectively.

**Note 4 - Unaudited Pro Forma Condensed Combined Statement of Operations Adjustments for the nine months ended September 30, 2025 and for the year ended December 31, 2024**

---

| | |
|:---|:---|
| **AA.** | Reflects the removal of the historical Star 26 amortization of $0.06 million and the addition of recorded pro forma amortization expense of $0.07 million for the nine months ended September 30, 2025 and the removal of the historical Star 26 amortization of $0.07 million and the addition of recorded pro forma amortization expense of $0.1 million for the year ended December 31, 2024 on the portion of the purchase price allocated to definite-lived intangible assets. |
| **BB.** | Represents $16.2 million in expense recognized from the issuance of 3,095,000 shares of common stock in connection with the 2025 Equity Plan. |
| **CC.** | Represents an aggregate of $2.5 million in losses from change in fair value of digital assets in connection with the digital assets acquired from the Company's exercise of the first and second tranches of the Darwin warrant |

---

**Note 5 - Earnings per share**

Represents the earnings per share calculated using the historical weighted average shares outstanding and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January 1, 2024. As the Business Combination is being reflected as if it had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted earnings per share assumes that the shares issued in connection with the Business Combination have been outstanding for the entire period presented.

---

| | | |
|:---|:---|:---|
|  | **For the <br> Nine Months<br> ended<br> September 30, <br> 2025** | **For the<br> Year Ended <br> December 31,<br> 2024** |
| Pro forma net income (loss) | $68230611 | $(164656937) |
| Weighted average shares outstanding of ordinary shares – basic | 16431121 | 9700871 |
| Weighted average shares outstanding of ordinary shares – diluted | 18133434 | 9700871 |
| Net income (loss) per share – basic | $4.15 | $(16.95) |
| Net income (loss) per share – diluted | $3.76 | $(16.95) |
| *Excluded securities:<sup>(1)</sup>* |  |  |
| &nbsp;&nbsp;&nbsp;Options to purchase common stock under Old Nukk equity incentive plan | 4823 | 4823 |
| &nbsp;&nbsp;&nbsp;Convertible notes payable that convert into common stock |  | 464217 |
| &nbsp;&nbsp;&nbsp;Stock purchase warrants | 16296673 | 16046231 |
|  | 16301496 | 16515271 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(1)** The potentially dilutive outstanding securities were excluded from the computation of pro forma net loss per share, basic and diluted, because their effect would have been anti-dilutive.